ArticleJournal of cardiovascular development and disease2022
A New Definition of Thrombocytopenia Following Transcatheter Aortic Valve Implantation: Incidence, Outcome, and Predictors.
Article in Journal of cardiovascular development and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Early post-TAVI thrombocytopenia recovery and subsequent subclinical leaflet thrombosis.European heart journal open · 2026Article
- Periprocedural Thrombogenicity Change Is Associated With Subclinical Leaflet Thrombosis Progression in Patients Undergoing Transcatheter Aortic Valve Implantation.Circulation reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of this study was to assess the incidence, outcomes, and risk factors associated with thrombocytopenia following TAVI according to a corrected platelet count (CPC), to avoid the bias of hemodilution/concentration. Methods: We analyzed patients who underwent TAVI in our center between 2009 and 2018. The study population were divided into three groups: none (NT), mild (MT), and severe (ST) postoperative thrombocytopenia. Primary outcomes were bleedings, length of hospital stay, and mortality. A multivariate logistic regression was performed to assess risk factors for ST. Results: A total of 907 patients were included in the analysis. MT was observed in 28.1% and ST in 2.6% of all patients. The following clinical outcomes were recorded: incidence of life-threatening and major bleeding (NT = 14.2%, MT = 20.8%, ST = 58.3%), the median length of hospital stay (NT = 8, MT = 10, ST = 14 days), in-hospital mortality (NT = 3.9%, MT = 6.3%, ST = 16.7%), and the overall significance in comparison with NT (p < 0.05). The logistic regression showed ST was associated with preoperative CPC, transapical access, diabetes mellitus, and the critical preoperative state. Conclusions: Worse clinical outcomes are associated with both MT and ST after TAVI. In particular, ST is associated with higher in-hospital and 30-day mortality. Management of modifiable baseline and procedural variables may improve this outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.